© 2018 Optum, Inc. All rights reserved.
Supporting Sustained Recovery for Opioid Use Disorder
RCPA Conference | Hershey, PA October 3, 2018
© 2018 Optum, Inc. All rights reserved.
Agenda
2
Scope of the opioid epidemic
Medication-assisted treatment (MAT)• What does MAT involve?
• What are the benefits and effects of MAT?
• How is MAT integrated into a comprehensive treatment plans to support long-term recovery?
Scope of the opioid epidemic
© 2018 Optum, Inc. All rights reserved.
The Denver Post | Sep 20, 2016
The Telegraph | June 13, 2017
CBS News | June 29, 2017
CBS News | May 23, 2017Stat News | August 22, 2016
The Guardian | March 6, 2018
4
© 2018 Optum, Inc. All rights reserved.
Opioid use disorder (OUD)
1. Retrieved from https://addiction.surgeongeneral.gov/
Addressing the challenges• Stigma around SUD can make people feel
ashamed or afraid to seek the help they need
• It is a chronic, complex disease difficult to treat
• The marketplace offers wide variability in treatment
• Members struggle to find effective evidence-based care
• Individuals are vulnerable to predatory practices
A medical conditionLike all substance use disorders (SUD), OUD is a condition characterized by a pattern of compulsive substance use in spite of the harmful consequences of repeated use.
Does not discriminateaffects individuals of all ages, gender, race, social and economic status
“A chronic brain disease; not a character flaw or moral failing” Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs and Health. 2016.
5
© 2018 Optum, Inc. All rights reserved.
Early exposure and dependence
1. Reinberg, S. (2017). Opioid Dependence Can Start in Just a Few Days. Retrieved from https://consumer.healthday.com/bone-and-joint-information-4/opioids-990/opioid-dependence-can-start-in-just-a-few-days-720750.html. 2. Muhuri, P. (2013). CBHSQ Data Review: Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. Retrieved from https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm . 3. Anuj Shah, A., Hayes, C., Martin, B., Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66. Retrieved from https://stacks.cdc.gov/view/cdc/44655..
Opioid dependence can start in just a few days.1
Risk of chronic opioid use increases with each additional day of opioid supplied starting with the third day.3
80% of heroin usersreport starting on prescription opioids prior to transitioning to heroin.2
6
© 2018 Optum, Inc. All rights reserved.
Death due to opioid overdose
7
25,000
20,000
15,000
10,000
’00 ’14’12’10‘08’06’04’02
5,000
Heroin and fentanyl Both Common prescription opioids
Deaths due to illicit opioids up 134% from 2012 to 2015.1
National per capita opioid prescribing rates decreased 13.1% from 2012 to 2015.2
1. National Center for Health Statistics, Centers for Disease Control and Prevention . 2. Guy GP Jr., Zhang K, Bohm MK, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015. MMWR. Morbidity and Mortality Weekly Report 2017;66:697–704. Retrieved from https://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm
© 2018 Optum, Inc. All rights reserved.
Prescription opioid use by age and gender
8
15%
30%
20%
12%
4%
13%
5%
19%
33%
16%
9%
3%
12%
6%
60+
50-59
40-49
30-39
26-29
18-25
13-17
<13
Opioid prescribing by age1
16%
17%
21%
8%
37%
1%
9%
14%
23%
11%
41%
1%
50-59
40-49
30-39
26-29
18-25
13-17
<12
Patients in opioid treatment by age and gender2
1. UnitedHealthcare large ASO employer 2017 claims experience. 2. UnitedHealthcare ASO covered lives 2016, served by Optum Behavioral Health.
MaleFemale
© 2018 Optum, Inc. All rights reserved.
CDC Guidelines for opioid prescribing
9
Opioids are not first-line therapy for chronic painNon-opioid and non-pharmacologic treatments are preferred
Short duration for acute pain3 days of therapy should be sufficient, longer than 7 days rarely needed
Avoid opioids in combination with benzodiazepinesAvoid these drugs in combination because of increased overdose risk
Offer MAT for OUDMAT has proven the most effective treatment for OUD
Lowest effective dose at startLess than 50 morphine equivalent dosing (MED) per day at treatment initiation
Minimize dose escalationAvoid increasing dosage to ≥ 90 MED per day
3
© 2018 Optum, Inc. All rights reserved.
When people try chiropractic care or physical therapy for back pain first,
1. Optum analytics based on UHC commercially insured population, 2017.
Prevention
10
Chronic back pain management
60% lesslikely to use opioids1
patients are
© 2018 Optum, Inc. All rights reserved.
Minimizing early exposure
11
Max of 49 MED per day and max 7-day supply on all new short-acting opioid scripts
Limit of two 7-day supply fills within a 60-day time frame
Narrowed refill window (75% to 90% used) on all opioid prescriptions to limit early refills and stockpiling
Prior authorization on all first-fill for a long-acting opioid and opioid-based cough preparations in pediatrics
Alignment with CDC guidelinesAggressive “first-fill” morphine-equivalent dose (MED) and days supply edits
© 2018 Optum, Inc. All rights reserved.
Optum experience
12
Pharmacy edits for short-acting prescription opiates
“First-fill” opioid scripts < 50 MED per day
94.7%compliance
“First-fill” opioid scripts < 50 MED per day
94.7%compliance
“First-fill” opioid scripts ≤ 7-days supply
95.2%compliance
“First-fill” opioid scripts ≤ 7-days supply
95.2%compliance
Opioid prescriptions dosed < 90 MED among
current chronic users
96.0%compliance
Opioid prescriptions dosed < 90 MED among
current chronic users
96.0%compliance
On average, 45% of “first-fill” scripts nationally are not in compliance with CDC guidelines1
Compliance with CDC guidelines
29.9%improvement29.9%
improvement13.5%
improvement13.5%
improvement4.5%
improvement4.5%
improvement
1. Note: Results are based on June 2017 vs December 2017 client data and short-acting opioid script volume and do not represent a guarantee of results.
Medication-assisted treatment (MAT)
© 2018 Optum, Inc. All rights reserved.
Substance use disorders are viewed as a chronic disease
14
Relapse is a common part of any chronic disease
SUD treatment is similar to medical interventions (e.g., the choice between surgery or medication)• Member’s previous clinical experiences,
individual psychosocial variables, effective treatment choices and outcomes
Chronic illness is best managed in the individual’s local community to aide the development of readily available local recovery supports
Direct correlation between treatment engagement and best outcomes• Treatment provided must be “person-centric” and individualized• Primary goal is to move from acute intervention to long-term
recovery• Acute treatment planning is based on an individual’s current
presentation, past substance use treatment, medical, psychiatric, and social history
• Long-term recovery is focused on each person’s strengths, challenges and barriers to treatment, and continuity of care
No correlation between the intensity of the treatment setting (i.e., inpatient, residential) and treatment engagement and outcomes
© 2018 Optum, Inc. All rights reserved.
Benefits of MAT
15
1. Calculated by Optum, based on relative risk ratios from the meta-analysis in: Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD011117. DOI: 10.1002/14651858.CD011117.pub2, pages 17 and 19.
Minimize withdrawal symptoms
Reduce opioid cravings
Prevent relapse
Restore normal physiological functioning
1
2
3
4
50%greater than detoxification or
psychosocial treatment alone.1
Chance of remission (no opioid misuse)
© 2018 Optum, Inc. All rights reserved.
MAT plays a critical role for those with OUD
16
It is the standard of care for treatment of OUD1
MAT uses FDA-approved medications with counseling and behavioral therapies to treat substance use disorders and prevent opioid overdose.2
1. National Drug Control Strategy: FY 2016 Budget and Performance Summary, p.7. 2. SAMHSA, Medication Assisted Treatment: Medication and Counseling Treatment. Retrieved from http://www.samhsa.gov/medication-assisted-treatment/treatment.
MethadoneBuprenorphineNaltrexone
© 2018 Optum, Inc. All rights reserved.
MAT works on opioid receptors
17
Three medications and three mechanisms of action:
Methadone: an opioid receptor AGONIST
• Fully activate opiate receptors
• Overdose shuts down the respiratory center and causes death
• Other agonists: heroin, morphine and oxycodone
Naltrexone: an opioid receptor ANTAGONIST
• Block and prevent activation of opiate receptors
• No overdose potential
• Cause immediate withdrawals if opioids are in the system
Buprenorphine: an opioid receptor PARTIAL AGONIST
• Partially activate opiate receptors
• Built in “ceiling effect” prevents overdose by themselves
• Cause immediate withdrawals if opioids are in the system
© 2018 Optum, Inc. All rights reserved.
Agonist therapy
18
Only provided by federally-regulated clinics• Synthetic, long-acting, full opioid agonist
• Chemically unlike morphine or heroin but acts on the same opioid receptors
Narcotic blockade by cross-tolerance• Eliminates symptoms of withdrawal
• Diminishes experience of “opiate euphoria”
• Reduces “drug hunger” or cravings
• Blocks “reinforcing intoxication”
Mt Sinai J Med. 2001 Jan;68(1):62-74
METHADONE
Benefits of maintenance• Ability to focus on activities of daily living
• Improvement in productive behaviors
– Employment, education, care-giving
– Marked drop in criminal activity and arrests
• Normalization of death rates compared to general public
© 2018 Optum, Inc. All rights reserved.
Replacement therapy
19
METHADONE
Induction
• Typical first dose is 20 mg to 30 mg (FDA methadone induction max is 40 mg)
• Steady state achieved within 10 days
Maintenance
• Typical dose is 60–120 mg/day
• Protracted side effects: sweating, constipation, weight gain, pregnancy
Discontinuation
• Slow taper: 10 mg/month until 30–40 mg/day, then 2–5 mg/month
• Conversion to buprenor-phine: 20–30 mg methadone and then stop for 72 hours
• Protracted withdrawals: malaise, depression, anxiety, insomnia, pain, cravings
Outcomes
• Maintenance: 50–80% 1-year retention rate– Discontinuation: 20–30%
abstinence after three years – Most relapse in first month– 59% used heroin over
the 2-year follow-up
• Greater criminal activity and incarceration rates
• Poor outcomes with co-morbid alcohol dependence and substance abuse
Mt Sinai J Med. 2001 Jan;68(1):62-74
© 2018 Optum, Inc. All rights reserved.
Partial agonist therapy
20
Brand products:* Suboxone® | Zubsolv® | Bunavail®
Regulated by the DEA (Drug Enforcement Agency)• Require special DEA prescribing license (DATA 2000)
• Eliminates the addictive, reinforcing and euphoric characteristics of a full agonist
Ambulatory and outpatient settingsThree stages of treatment: 1. Induction2. Stabilization3. Maintenance
Treatment considerations• Absence of opiates in the system
• Avoidance of sedative use
• Can be used at all levels of care
• Can be used while treating psychiatric and medical comorbidities
• Can be used with MAT for nicotine use disorder
• Cannot be used simultaneously with naltrexone or methadone
*Contains small amount of naloxone | **Except naltrexone
BUPRENORPHINE
© 2018 Optum, Inc. All rights reserved.
Stages of treatment
21
BUPRENORPHINE
Intake
• Establish suitability for treatment
• Discuss substance use history
• Assess readiness for change
• Confirm support systems/networks
• Review treatment plan/expectations
• Sign patient contract
Induction
Day 1• Member in moderate
withdrawal• Initiate induction• Additional medications
as needed
Day 2• Re-evaluate• Discuss side effects,
adjust dosage • Prescription only to last until
next visit• Review ongoing counseling
and sober support use
Stabilization
• Continue to assess withdrawal symptoms
• Member begins stable daily dose
• Begin counseling, group therapy and sober supports
• Relapse prevention and planning
• Weekly follow-up and drug screening
• Prescription only to last until next visit
Maintenance
• Continue stable daily dosage
• Decrease visit frequency
• Continue UDS with prescriptions
Taper
• Long taper: more than 30 days
• Moderate taper:14 to 30 days
• Rapid taper:3 to 5 days
© 2018 Optum, Inc. All rights reserved.
Opioid “detox”: Facts and fictions
22
Opiate withdraw symptoms
• Symptoms of opioid withdrawal are not life-threatening
• Clinical management does not require 24-hour nursing care
• Untreated withdrawal symptoms often result in continued use
Opioid withdrawal management
• Detox only is not considered treatment for OUD
• Detox only does not decrease the incidence of relapse
• Detox only does not increase community sobriety or tenure
• Detox only does increase the risk for unintentional overdose
© 2018 Optum, Inc. All rights reserved.
“Detox”
23
Rapid induction-reduction with buprenorphine
BUPRENORPHINE
Induction phase
• 1 to 2 days
• Typically seen in inpatient detox or enhanced programming
Reduction phase
• Rapid reduction: 3 to 5 days– “Detox” has no compelling reason– More likely to overdose upon relapse– Has not considered treatment
• Moderate reduction: 14 to 30 days– No compelling reason for short-term
reduction– Unwilling or unable to engage in
treatment with ongoing treatment
• Long reduction: 30 days or longer– Compelling reason to engage in
rehabilitation– Unwilling or unable to engage in on-
going therapy
Post-taper phase
• Indefinite period
• Continue individual therapy, group therapy, sober supports
• Address medical, behavioral and social problems
© 2018 Optum, Inc. All rights reserved.
Antagonist therapy
24
• Used to prevent relapse or diminish the effect of opioid use
• Naltrexone causes withdrawal symptoms if an opiate is in the system – Oral challenge for 5–7 days followed
by intramuscular injection
– Oral challenge for 5–14 days after detox or methadone conversion
NALTREXONE
Two dosing schedules for oral Naltrexone• 50 mg/day; can increase to 100 mg/day if needed
• 100 mg M–W–F +150 mg over the weekend
One dosing schedule for injectable naltrexone• Given as a 380 mg intramuscular injection dose
every four weeks
• Special pharmacy order; not self-administered
• Vivitrol®: brand name of long acting formulation
© 2018 Optum, Inc. All rights reserved.
MAT considerations for special populations
25
Pregnant women• MAT for maintenance is preferred over MAT for withdrawals
– Either methadone or buprenorphine can be prescribed; however, if a pregnant patient is stable on methadone do not change to buprenorphine
– Infants born to women who received buprenorphine during pregnancy 1) developed milder neonatal opioid withdrawal symptoms (NAS) than those born to women who received methadone, and 2) needed fewer post-delivery hospital days
– MAT should begin immediately when a pregnant opiate addict presents for treatment; MAT should be continued through the pregnancy
– If a patient is using buprenorphine, the drug should be used alone (without naloxone)
• Breastfeeding is encouraged on both medications
Adolescents• All treatment options are to be considered
– Some MAT are not FDA-approved for adolescents – Clinical reasoning for not providing MAT should always be documented
BUPRENORPHINE
© 2018 Optum, Inc. All rights reserved.
What our experience shows
26
1. Based on Healthcare Analytics review from 11-1-2014 to 10-31-2015 claims data for Optum Commercial Business; there were 10,373 members who were admitted to a facility-based level of care with an opiate-based primary diagnosis.2. McLellan AT1, Arndt IO, Metzger DS, Woody GE, O’Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993 Apr 21;269(15):1953-9.
© 2018 Optum, Inc. All rights reserved.
Dispelling a myth about MAT
27
Many objections to MAT are based on the belief that it replaces one dangerous drug with another
SUDs are characterized by harmful consequences of repeated useDSM-5 criteria for diagnosis: Maladaptive Pattern of Substance Use • Leading to clinically significant impairment
or distress over 12 months• Note: Withdrawal and tolerance symptoms by
themselves do not denote a substance use disorder
Most people using MAT are quite functional again and are able to fulfill their responsibilities
a treatmentMAT is
© 2018 Optum, Inc. All rights reserved.
MAT need significantly exceeds capacity1
28
Physicians are not prescribing.
1. August 2015, Vol 105, No. 8, American Journal of Public Health. 2. Vestal, C. In Drug Epidemic, Resistance to Medication Costs Lives,” The PEW Charitable Trusts. January 11, 2016. 3. Knudsen HK, Roman PM, Oser CB. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine 2010;4(2):99–107. 4. Knudsen HK,, Abraham AJ, Roman PM. Adoption and Implementation of Medications in Addiction Treatment Programs. Journal of Addiction Medicine 2011 5(1): 21–27.
Only 3.5% of 900,000 U.S. physicians who can write prescriptions for opioid painkillers have obtained a DATA 2000 waiver to prescribe buprenorphine ― and only a fraction of those licensed actually prescribe it.2
Only 23% of public and less than 50% of private-sector treatment programs offer any FDA-approved medications to treat SUD/OUD.3,4
Even in programs that do offer MAT, only 34.4% of patients receive it.4
© 2018 Optum, Inc. All rights reserved.
Importance of community tenure
29
Treatment in an individual’s home community improves the chance of sustained recovery Allows people to create a readily accessible support system (primary care providers, mental health professionals, friends, family, peers, and community sober supports).
ASAM treatment guidelines suggesting that psychosocial treatment in conjunction with MAT “should include ... links to existing family supports and referrals to community services.”
© 2018 Optum, Inc. All rights reserved.
The rising trend of destination treatment
30
A cottage industry has formed to influence consumers to choose high-cost, ineffective treatment centers• Most consumers are not aware of what treatment options exist.• Stigma causes many to seek anonymous help.• Call centers advertise aggressively (online, late-night television, billboards) to connect
with consumers when they are ready to engage.• Destination centers buy these leads and charge exorbitant fees for inadequate care.
1. Optum comparative analysis of average annual readmission rates for in-network and out-of-network residential SUD treatment programs authorized for members from January to December 2017. Data includes membership in all age cohorts from the commercial book of business. Bolstrom, May 2018 2. Comparison of average 90-day episode-of-care cost for out-of-network residential treatment ($42212) to that for in-network residential treatment ($10440-$15291); “Episode of Care” is defined as claims between three days prior to admission through 90 days after discharge; Bolstrom, May 2018 3. Increase in claims for four common lab test CPT codes for substance use; Source: FAIR Health Study: The Impact of the Opioid Crisis on the Healthcare System: A Study of Privately Billed Services, September 2016.
105%–142% higher30- and 90-day readmission rates per year1
304% higher cost for 90-day episodes of care2
Over 1,000%increase in lab testing utilization from 2011–143
© 2018 Optum, Inc. All rights reserved.
The ER as a first step to long-term treatment
31
“The emergency department is a health care setting in which patients with opioid use disorders commonly present …
Emergency physicians are thus uniquely positioned to intervene to help patients with opioid use disorders at a critical moment in the addiction cycle.”
— David Kan, CSAM
SEE NOTES: This is one area where the ER, health plans and community providers can work together to have an effective intervention with follow-up arranged before discharge
Supporting long-term recovery
© 2018 Optum, Inc. All rights reserved.
Support long-term recovery
33
Help individuals avoid relapse Support chronic populations and recovery1. Connect individuals with certified peer support
specialists– Uniquely qualified support resources that have made the journey
from substance abuse to recovery themselves
2. Equip individuals with recovery tools– Mobile apps offer guidance, reminders and immediate
help when needed
3. Continuously monitor pharmacy claims data – Inform doctors and pharmacists how to reach out to individuals
who may need extra support to avoid relapse– Drug Utilization Review (DUR): concomitant use of opioids and
MAT
1. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide. Accessed July 2017; 2. Ann Intern Med. 2016; 164:1-9; 3. Psychiatric Serv in Advance. 2016
40–60%average relapse rate amongst opioid abusers in the U.S.1
91%of patients who overdose receive an opioid prescription within 10 months.2
© 2018 Optum, Inc. All rights reserved.
1Results from an Optum January 2017 analysis of 338 members who enrolled in Optum peer support services between February 1, 2014 and February 28, 2016; results are within six months after enrollment compared to six months prior to enrollment; participants had continuous eligibility for six months pre- and post-referral and at least one behavioral health (mental health and/or substance use) claim during that period; Source: Ten Eyck, 11/06/2017.
Reduction in inpatient days124%
Long-term recovery: Peer support
35
Offer personalized assistance through certified peer support specialists
Engagement with peers is important in all stages of treatment and recovery
Reduction in overall behavioral health costs1
21%• Engage individuals to design recovery
plans based on strengths and goals• Coordinate with the care system
to ensure adherence• Demonstrate they are successful
in their own recovery
Discussion
Jeffrey MeyerhoffSenior Medical Director, Optum Behavioral HealthEmail: [email protected]: (763) 283-3114
Thank you. Contact information: